New data show that prostate-specific membrane antigen (PSMA) PET–CT can reveal the anatomical location of prostate cancer recurrences in patients diagnosed with nonmetastatic castration-resistant disease according to conventional imaging. The findings necessitate a new evaluation of the role of PSMA PET–CT in this setting compared with standard-of-care imaging and treatment approaches.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Clinical Drug Investigation Open Access 13 July 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mottet, N. et al. EAU — ESTRO — ESUR — SIOG guidelines on prostate cancer. EAU https://uroweb.org/guideline/prostate-cancer/ (2019).
Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol. 31, 3800–3806 (2013).
Higano, C. Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients? Nat. Rev. Urol. 16, 335–336 (2019).
Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. https://doi.org/10.1016/j.eururo.2019.01.049 (2019).
Fendler, W. P. et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-1050 (2019).
Palma, D. A. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393, 2051–2058 (2019).
Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408–1418 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.O. holds institutional research grants from Bayer, Ferring, Merck and Varian, has received consultancy fees from Bayer, Ferring and Janssen, and travel support from Ferring, with all funds going to his institution.
Rights and permissions
About this article
Cite this article
Ost, P. PSMA PET–CT redefines nonmetastatic castration-resistant prostate cancer. Nat Rev Urol 17, 133–134 (2020). https://doi.org/10.1038/s41585-019-0268-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0268-1
This article is cited by
-
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Clinical Drug Investigation (2022)
